Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trials

MLA

Philip Mease, et al. “Efficacy and Safety of Tanezumab, NSAIDs, and Placebo in Patients with Moderate to Severe Hip or Knee Osteoarthritis and a History of Depression, Anxiety, or Insomnia: Post-Hoc Analysis of Phase 3 Trials.” Current Medical Research and Opinion, vol. 38, Aug. 2022, pp. 1909–22. EBSCOhost, https://doi.org/10.1080/03007995.2022.2113689.

APA

Philip Mease, Louis Kuritzky, Wendy L. Wright, Theresa Mallick-Searle, Robert Fountaine, Ruoyong Yang, Mojgan Sadrarhami, Warachal Faison, Elizabeth Johnston, & Lars Viktrup. (2022). Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trials. Current Medical Research and Opinion, 38, 1909–1922. https://doi.org/10.1080/03007995.2022.2113689

Chicago

Philip Mease, Louis Kuritzky, Wendy L. Wright, Theresa Mallick-Searle, Robert Fountaine, Ruoyong Yang, Mojgan Sadrarhami, Warachal Faison, Elizabeth Johnston, and Lars Viktrup. 2022. “Efficacy and Safety of Tanezumab, NSAIDs, and Placebo in Patients with Moderate to Severe Hip or Knee Osteoarthritis and a History of Depression, Anxiety, or Insomnia: Post-Hoc Analysis of Phase 3 Trials.” Current Medical Research and Opinion 38 (August): 1909–22. doi:10.1080/03007995.2022.2113689.